Skip to content

A Clinical Study of Xuebijing Injection in Patients With Sepsis induced by Intra-abdominal Infection

A Clinical Study of Xuebijing Injection in Patients With Sepsis induced by Intra-abdominal Infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001235
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-05-16
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis induced by Intra-abdominal Infection

Interventions

Exposome: Syndrome of Internal Blockage by Static Blood and Toxin:Conventional sepsis treatment + Xuebijing, 100 ml per administration, twice daily, for 5 days
Non-exposome Group: Other TCM Syndrome Types:Conventional sepsis treatment + Xuebijing, 100 ml per administration, twice daily, for 5 days

Sponsors

Beijing Friendship Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1: Age = 18 years 2: Meets the Sepsis 3.0 diagnostic criteria 3: Sequential Organ Failure Assessment score of 2–14 points 4: Intra-abdominal infection 5: The traditional Chinese medicine (TCM) syndrome types include stasis-toxin internal retention, toxic heat internal exuberance, fu-qi obstruction, qi-yin exhaustion, and yang qi sudden collapse 6: Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1: Patients with a diagnosis of sepsis for more than 48 hours were included. 2: Pregnant or lactating women 3: severe primary disease affecting survival. 4: continuous use of immunosuppressants within the past 6 months, or organ transplant recipients. 5: participation in another clinical trial within 30 days. 6: Acute Physiology And Chronic Health Evaluation II score = 30 7: Allergy to any component of Xuebijing or allergic constitution

Design outcomes

Primary

MeasureTime frame
Sequential Organ Failure Assessment;

Secondary

MeasureTime frame
C-reactive protein (CRP) ;bilirubin;TCM symptom score ;procalcitonin;Disseminated Intravascular Coagulation Score;28-day mortality rate ;activated partial thromboplastin time ;fibrinogen;length of hospital stay (LOS) ;oxygenation index ;international normalized ratio;Acute Physiology And Chronic Health Evaluation II;D-Dimer;prothrombin time;creatinine ;platelet;Duration of Mechanical Ventilation;Intensive Care Unit length of stay;Etiological examination;

Countries

china

Contacts

Public ContactQi Wenjie

Beijing Friendship Hospital,Capital Medical University

qi_wenjie@ccmu.edu.cn010-63138749

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026